About 27 results found for searched term "DS1" (0.064 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M3404 | URB597 | FAAH |
| KDS-4103 | ||
| URB597 is a potent, orally bioavailable FAAH inhibitor with IC50 of 4.6 nM, with no activity on other cannabinoid-related targets. | ||
| M4948 | SAR191801 | PGE synthase |
| hPGDS-IN-1 | ||
| hPGDS-IN-1 is a hPGDS inhibitor ,with IC50 of 12 nM in the Fluorescence Polarization Assay or the EIA assay. | ||
| M7740 | DS1 | Others |
| δ-GABAA receptors are emerging as an important pharmacological target. | ||
| M9180 | Pyridostatin Trifluoroacetate Salt | DNA/RNA Synthesis |
| Pyridostatin TFA salt; PDS; CAS# 1085412-37-8(free base) | ||
| Pyridostatin Trifluoroacetate Salt is a G-quadruplexe stabilizer, with a Kd of 490 nM. | ||
| M9533 | DS-1001b (Safusidenib t-Butylamine) | Isocitrate Dehydrogenase (IDH) |
| Safusidenib | ||
| DS-1001b (Safusidenib t-Butylamine) is a potent, orally bioavailable, selective mutant IDH-1 (Isocitrate Dehydrogenase-1) inhibitor with antitumor activity. | ||
| M9914 | Valemetostat | EZH2 |
| DS-3201；DS-3201b | ||
| Valemetostat (DS-3201, DS-3201b) is a first-in-class dual inhibitor targeting EZH1 and EZH2. It can be used in the study of adult T-cell leukemia/lymphoma. | ||
| M10936 | Taletrectinib | Trk |
| DS-6051b; AB-106; IBI-344 | ||
| Taletrectinib (DS-6051b) is a potent orally active next-generation selective ROS1/NTRK inhibitor. Taletrectinib is 0.207, 0.622, 2.28, and 0.98 nM, respectively IC50 It has a strong inhibitory effect on recombinant ROS1, NTRK1, NTRK2 and NTRK3. Taletrectinib also inhibits ROS1 G2032R and other ANTI-Crizotinib ROS1 mutants. | ||
| M14197 | DS16570511 | Calcium Channel |
| DS16570511 is cell-permeable inhibitor of the mitochondrial calcium uniporter, which blocks the MCU- or MICU1-dependent increase of Ca2+ influx. | ||
| M14426 | URB-597 | FAAH |
| KDS-4103 | ||
| URB-597 (KDS-4103) is an orally bioavailable and selective FAAH inhibitor. | ||
| M14691 | DS18561882 | Others |
| DS18561882 is a highly potent, isozyme-selective methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) inhibitor with an IC50 value of 0.0063 μM. DS18561882 also has inhibitory effect on MTHFD1 (IC50=0.57 μM). | ||
| M21062 | DS-3801b | Others |
| DS-3801b is a non-mescaline GPR38 agonist, DS-3801b is expected to be a novel gastrointestinal prokinetic agent for the study of functional gastrointestinal disorders such as gastroparesis and chronic constipation. | ||
| M21091 | DS69910557 | Others |
| DS69910557 is an oral parathyroid hormone (PTH) type 1 receptor (PTHR1) inhibitor that is being developed as a hypercalcemic compound. | ||
| M21271 | DS-1971a | Sodium Channel |
| DS-1971a is a potent, homozygous form-selective aryl sulfonamide NaV1.7 inhibitor for the treatment of neuropathic pain. | ||
| M21487 | Valemetostat tosylate | Histone Methyltransferase |
| DS-3201 tosylate | ||
| Valemetostat tosylate (DS-3201 tosylate) is a first-in-class EZH1/2 inhibitor with IC50 < 10 nM. Valemetostat tosylate can be used in the study of relapsed and refractory peripheral T cell lymphoma. | ||
| M22177 | DS-1040 Tosylate | Others |
| DS-1040 Tosylate | ||
| M24699 | Vandortuzumab vedotin | Antibody-Drug Conjugates (ADCs) |
| DSTP 3086S; RG 7450; MSTP2109A | ||
| Vandortuzumab vedotin (DSTP 3086S) is an antibody-drug-conjugate to target prostate cancer. | ||
| M24828 | Trastuzumab deruxtecan | Drug-Linker Conjugates for ADC |
| DS-8201; DS-8201a; T-DXd | ||
| Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, and a topoisomerase I inhibitor. Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer. | ||
| M28955 | DS-1205b free base | TAM Receptor |
| DS-1205b free base is a potent and selective inhibitor of AXL kinase, with an IC50 of 1.3 nM. DS-1205b free base also inhibits MER, MET, and TRKA, with IC50s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo. | ||
| M29300 | DS28120313 | Others |
| DS28120313 (compound 32) is an orally hepcidin production inhibitor with an IC50 of 0.093 μM. | ||
| M29534 | DS44960156 | Dehydrogenase |
| DS44960156 is a selective Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) inhibitor, with IC50 values of 1.6 μM and >30 μM for MTHFD2 and MTHFD1, respectively. | ||
| M29567 | DS08210767 | Thyroid Hormone Receptor |
| DS08210767 is a highly potent, orally bioavailable PTHR1 antagonist with IC50 of 90 nM. | ||
| M29711 | CMLD010509 | c-Myc |
| SDS-1-021 | ||
| CMLD010509 (SDS-1-021) is a highly specific inhibitor of the oncogenic translation program supporting multiple myeloma (MM)-including key oncoproteins such as MYC, MDM2, CCND1, MAF, and MCL-1. CMLD010509 (SDS-1-021) shows an IC50 below 10 nM for most MM cell lines and induces apoptosis. CMLD010509 (SDS-1-021) is a potent and selective translation inhibitor through an eIF4E phosphorylation-independent mechanism. | ||
| M30450 | Mizagliflozin | SGLT |
| DSP-3235 free base; KGA-3235 free base; GSK-1614235 free base | ||
| Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a Ki of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation. | ||
| M39649 | NDSB-201 | Others |
| NDSB-201 consists of a pyridine group attached to a propane chain, which in turn is attached to a sulfonate group. | ||
| M45236 | DS17701585 | Epigenetic Reader Domain |
| DS17701585 is a selective, orally active inhibitor of EP300 and CBP with IC50 values of 0.040, 0.15, 0.45, and 0.70 µM for CBP, EP300, H3K27, and SOX2, respectively.CAS 번호128-52-56-5 | ||
| M54525 | DSB-1522 | PARP |
| DSB-1522 is a PARP1 inhibitor that can be used in tumor-related studies. | ||
| M56440 | DS12881479 | MNK |
| DS12881479 is a potent and selective Mnk1 inhibitor with an IC50 value of 21 nM. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
